CN105348217A - Traditional Chinese medicine composition for treating hyperlipidemia - Google Patents
Traditional Chinese medicine composition for treating hyperlipidemia Download PDFInfo
- Publication number
- CN105348217A CN105348217A CN201510902218.0A CN201510902218A CN105348217A CN 105348217 A CN105348217 A CN 105348217A CN 201510902218 A CN201510902218 A CN 201510902218A CN 105348217 A CN105348217 A CN 105348217A
- Authority
- CN
- China
- Prior art keywords
- compound
- hyperlipidemia
- pharmaceutical composition
- medicine composition
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
Abstract
The invention relates to a traditional Chinese medicine composition for treating hyperlipidemia. The traditional Chinese medicine composition contains an effective amount of a compound and a pharmaceutically acceptable carrier, wherein the structure of the compound is shown in the description. The compound of the traditional Chinese medicine composition has a remarkable hyperlipidemia treatment effect and can be developed into a clinically effective new medicine composition.
Description
Technical field
The present invention relates to field of medicaments, specifically, the present invention relates to a kind of pharmaceutical composition for the treatment of hyperlipidemia.
Background technology
Hyperlipidaemia (hyperlipidemia, HLP) be common disease, the frequently-occurring disease of society, it is a kind of disease that people's HypercholesterolemicRats is not normal, blood plasma inner lipid concentration exceedes normal high limit, with the primary disease causing human death, cardiovascular and cerebrovascular diseases has very close relationship.Associated disease and the risk factor of atherosclerosis, fatty liver, coronary heart disease, diabetes, obesity etc.Along with the change of growth in the living standard and mode of life, the sickness rate of hyperlipidaemia is in the trend gone up year by year.Epidemiology survey shows, and the morbidity of China's hyperlipidaemia, more than 7%, about has hyperlipidaemia patient 9,000 ten thousand at present, and wherein about have the patient of 3,600 ten thousand at use lipid lowering agent, lipid regulating agent account for 1/4 of cardiovascular disease medicine.Therefore, the medicine that research safety is effective, reliable and stable is to control and reduce the sickness rate of cardio-cerebrovascular diseases, case fatality rate is significant.
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical composition for the treatment of hyperlipidemia.
In order to realize object of the present invention, the invention provides a kind of compound for the treatment of hyperlipidemia, this compound has having structure:
The present invention also provides a kind of pharmaceutical composition for the treatment of hyperlipidemia, and described pharmaceutical composition includes the compound of effective amount and pharmaceutically acceptable carrier, and described compound has having structure:
Preferably, described pharmaceutically acceptable carrier is thinner, disintegrating agent, tackiness agent, lubricant, stablizer or corrigent.
Preferably, described thinner is sugar derivatives, starch derivative or derivatived cellulose.
Preferably, described thinner is lactose.
Preferably, described pharmaceutical composition is powder, microgranules, granule, capsule or tablet.
The present invention also provides the purposes of compound in the medicine of preparation treatment hyperlipidemia, and this compound has having structure:
Term used herein " pharmaceutically acceptable " refers to not eliminate the biologic activity of compound as herein described or the material of character, as carrier or thinner.This kind of material is applied to and individual does not cause undesirable biological action or not with harmful way and any component interaction comprised in its composition.
" pharmaceutically acceptable carrier " comprises any and all solvents as the term is employed herein, dispersion medium, coating material, tensio-active agent, antioxidant, sanitas (such as antiseptic-germicide, anti-mycotic agent), isotonic agent, absorption delay agent, salt, sanitas, drug stabilizing agent, tackiness agent, vehicle, disintegrating agent, lubricant, sweeting agent, correctives, dyestuff etc. and its combination, this is well-known to those skilled in the art (for example, see Remington'sPharmaceuticalSciences, 18thEd.MackPrintingCompany, 1990, pp.1289-1329).Except with except the inconsistent carrier of activeconstituents, consider to use any conventional carrier in treatment or pharmaceutical composition.
The Be very effective of compounds for treating hyperlipidemia of the present invention, can be developed to pharmaceutical composition effectively new clinically.
Embodiment
Below by way of the description of embodiment, the invention will be further described, but this is not limitation of the present invention, those skilled in the art are according to basic thought of the present invention, various amendment or improvement can be made, but only otherwise depart from basic thought of the present invention, all within the scope of the present invention.
Experimental example
The structural formula of target compound is:
Choose cleaning grade SD rat 120, body weight 180-220g, male and female half and half, after rat adaptability is fed 7 days, tail venous blood sampling, detects blood lipid level, get rid of non-health laboratory animal to the impact of experimental result, and sub-cage rearing after rat being divided into 4 groups at random according to body weight, sex, be respectively normal group, model group, positive drug group, administration group, often organize 30.Except normal group gives normal diet nursing, all the other are respectively organized rat and first give vitamins D
3700000 IU/kg, gavage (normal group gives the physiological saline of equal volume) in 3 days, then raise with high lipid food (% by weight): cholesterol 1%, propylthiouracil 0.61%, Glycocholate sodium 0.35%, lard 5%, basal feed 93.04%, raises 8 weeks, to cause hyperlipidemia animal model.
After modeling the 3rd day starts administration, and each group dosage is as follows: normal group and model group, give physiological saline gavage 1mL/100g body weight; Positive drug group, atorvastatin solution 0.09mg/ml, gives gavage 1mL/100g body weight; Administration group, the target compound of 0.01g adds 10000mL normal saline and becomes suspension, gives gavage 1mL/100g body weight.1 times/day, successive administration 20d.
The rat 25% urethane 3ml/kg intraperitoneal injection of anesthesia of each group, after 30 minutes, fixed at back respectively by each group of rat, cut abdominal cavity open, abdominal aortic blood 5m1 does blood lipids index.The centrifugal 10min of abdominal aortic blood 5m1, whizzer 5000 turns/min, prepares serum.Enzyme process is adopted to detect serum TG.
The results are shown in following table.
| Group | TG(mmol/L) |
| Normal group | 0.27±0.04 |
| Model group | 0.43±0.03 |
| Positive drug group | 0.30±0.04 |
| Administration group | 0.29±0.03 |
As seen from the above table, the effect there was no significant difference of positive drug group and administration group.
Claims (7)
1. treat a compound for hyperlipidemia, it is characterized in that, this compound has having structure:
2. treat a pharmaceutical composition for hyperlipidemia, it is characterized in that, described pharmaceutical composition includes the compound of effective amount and pharmaceutically acceptable carrier, and described compound has having structure:
3. the pharmaceutical composition for the treatment of hyperlipidemia according to claim 2, is characterized in that, described pharmaceutically acceptable carrier is thinner, disintegrating agent, tackiness agent, lubricant, stablizer or corrigent.
4. the pharmaceutical composition for the treatment of hyperlipidemia according to claim 3, is characterized in that, described thinner is sugar derivatives, starch derivative or derivatived cellulose.
5. the pharmaceutical composition for the treatment of hyperlipidemia according to claim 4, is characterized in that, described thinner is lactose.
6. the pharmaceutical composition for the treatment of hyperlipidemia according to claim 3, is characterized in that, described pharmaceutical composition is powder, microgranules, granule, capsule or tablet.
7. the purposes of compound in the medicine of preparation treatment hyperlipidemia, it is characterized in that, this compound has having structure:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510902218.0A CN105348217A (en) | 2015-12-08 | 2015-12-08 | Traditional Chinese medicine composition for treating hyperlipidemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510902218.0A CN105348217A (en) | 2015-12-08 | 2015-12-08 | Traditional Chinese medicine composition for treating hyperlipidemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105348217A true CN105348217A (en) | 2016-02-24 |
Family
ID=55324302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510902218.0A Pending CN105348217A (en) | 2015-12-08 | 2015-12-08 | Traditional Chinese medicine composition for treating hyperlipidemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105348217A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5561142A (en) * | 1994-04-26 | 1996-10-01 | Merck & Co., Inc. | Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity |
-
2015
- 2015-12-08 CN CN201510902218.0A patent/CN105348217A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5561142A (en) * | 1994-04-26 | 1996-10-01 | Merck & Co., Inc. | Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9168308B2 (en) | Compositions and methods for nutritional supplementation | |
| US8697086B2 (en) | Use of Antrodia camphorata for treating diseases | |
| KR101512495B1 (en) | Applications of arctigenin in formulating medicines for preventing or treating diseases related to red blood cell reduction | |
| JP6209579B2 (en) | Pharmaceutical composition that is regarded as a supplementary medicine | |
| CN104922176B (en) | A kind of application of Flos Chrysanthemi Indici extract | |
| WO2010081259A1 (en) | A composition comprising extraction of fucoxanthin | |
| CN108619168A (en) | A kind of Remedies for diabetes and its preparation and application | |
| CN105348217A (en) | Traditional Chinese medicine composition for treating hyperlipidemia | |
| US20210330750A1 (en) | Lactate-protected hypoglycemia to treat glycolysis dependent pathological conditions, in particular cancer | |
| CN105503723A (en) | Pharmaceutical composition for treating coronary heart disease | |
| JP2014181232A (en) | Blood sugar level elevation inhibitor of capsicum frutescens fermentation product using aspergillusoryzae | |
| CN105330676A (en) | Drug combination for treating chronic cardiac failure | |
| CN104524568B (en) | A kind of pharmaceutical composition for treating obesity and its application | |
| Pohorska et al. | Reconstruction of NK cells during complex cancer treatment | |
| CN105622562B (en) | A kind of pharmaceutical composition for treating cardiovascular and cerebrovascular disease | |
| WO2015062167A1 (en) | Application of metrnl protein in preparing hypolipidemic, antihypertensive medicine | |
| CN103977059A (en) | Special vein nutrient liquid for treating hundestaupe virus and parvovirus infected dog and application method thereof | |
| CN106822123A (en) | A kind of pharmaceutical composition for treating cardiovascular and cerebrovascular disease | |
| CN105348171B (en) | A kind of pharmaceutical composition treating knee osteoarthritis | |
| US20190142891A1 (en) | Fermentation product of mung bean hull and uses of the same | |
| WO2020020317A1 (en) | Metformin compound composition and use thereof | |
| KR20210097487A (en) | Composition for preventing, improving or treating sleep disorders comprising fucoidan | |
| CN103550222A (en) | Applications of chaetocin in preparing medicament for preventing and treating diabetes | |
| CN104784192A (en) | Application of clam meat oligosaccharide in preparation of hypoglycemic drugs and preparation method of clam meat oligosaccharide | |
| US8524245B2 (en) | Use of antrodia camphorata for treating gout |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160224 |